Pharmafile Logo

TVF Communications

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Don’t lose sight of behavioural insight

If we are being asked to demonstrate ROI, we first need to agree on the value of the outcome

Top 10 Most Important Advisor Questions: Unmet Needs

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's the first one to keep...

Impetus Digital

- PMLiVE

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

- PMLiVE

US government awards $1.4bn for development of COVID-19 vaccines and therapeutics

The funding includes a contract with Regeneron for a next-generation antibody therapy

- PMLiVE

Study suggests self-reported information could help predict MS progression

Predicting MS progression could improve treatment and care outcomes for patients

- PMLiVE

Creating the right foundations for omnichannel success

Changing behaviours across commercial organisations will allow pharma to achieve true customer-centricity by delivering the customer experiences its stakeholders demand

Sarah Seilly Medical Education Appointment

Onyx Health Welcomes Sarah Seilly as Head of Medical Education

Leading healthcare marketing communications agency, Onyx Health, has bolstered its team with the appointment of a new Head of Medical Education, Sarah Seilly. This strategic addition to the team reflects...

Onyx Health

- PMLiVE

LEO Pharma to acquire Timber Pharmaceuticals in deal worth up to $36m

The transaction gives LEO access to Timber’s lead investigational candidate, TMB-001

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Novavax’s updated COVID-19 vaccine candidate shows promise against emerging subvariants

The protein-based vaccine generated immune responses against the fast-spreading ‘Eris’ strain

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links